HIGHLIGHTS
- who: Stefan Heinrich and Hauke Lang from the Department of General, Visceral and Transplantation Surgery, University Hospital of Mainz have published the article: Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits, in the Journal: (JOURNAL)
SUMMARY
The standard treatment for patients with resectable pancreatic cancer is surgery followed by adjuvant chemotherapy (CTx): after the ESPAC-1 trial had suggested a survival benefit for an adjuvant CTx, Oettle et_al have demonstrated a significant improvement of the recurrence-free and overall survivals for patients with pancreatic cancer after a curative resection. Theoretical advantages of neoadjuvant . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.